Results 81 to 90 of about 10,093 (182)

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 769-777, August 2026.
Key Points In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...
Marjolein Cornet, Peter W. Hellings, Martin Desrosiers, Martin Wagenmann, Richard Follows, Laura Walrave, Luz Adriana Jimenez, Lee Tombs, Dawn Edwards, Peter Howarth, Joseph K. Han   +10 more
wiley   +1 more source

A Meta‐Analysis of Anti‐Thyroid Peroxidase Antibody and Omalizumab Response in Chronic Spontaneous Urticaria

Clinical &Experimental Allergy, EarlyView.
Ju Hyun Lee, Min Jung Geum, Do‐Young Kim, Young‐Mi Ah, Yun Mi Yu   +4 more
wiley   +1 more source

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 852-879, August 2026.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo, Deanna Gigliotti, Eugenio De Corso, Stella Lee, Benjamin S. Bleier, Christopher J. Chin, Marie‐Noelle Corriveau, Valerie Hox, Claire Hopkins, Peter H. Hwang, Arif Janjua, Ludger Klimek, Daniel Lee, John Lee, Amber Luong, Geoffrey Mortuaire, Joaquim Mullol, Zara M. Patel, John Scott, Doron Sommer, Leigh Sowerby, Marc Tewfik, Beatrice Voizard, Martin Wagenmannm, Sarah K. Wise, Jonathan Yip, Quirina Thompson, Martin Desrosiers, Yvonne Chan   +28 more
wiley   +1 more source

New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs.
Ana Maria Copaescu, Valentina Gueli, Jitesh Chahuan, Waad Albalawi, Giovanna Sfriso, Mattia Giovannini, Leticia de las Vecillas, Aspasia Karavelia, Marina Labella, Ruben Fernandez‐Santamaria, Francesca Mori, Lene H. Garvey, Patrizia Bonadonna, Maria Jose Torres   +13 more
wiley   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Omalizumab in the management of patients with allergic (IgE-mediated) asthma

Journal of Asthma and Allergy, 2009
Thomas SandströmDepartment of Respiratory Medicine and Allergy, University Hospital, Umeå, SwedenAbstract: Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma.
Thomas Sandström
doaj  

Patient Journey, Treatment Patterns, and Disease Burden of Patients With Idiopathic Hypereosinophilic Syndrome

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Idiopathic hypereosinophilic syndrome (I‐HES) is a rare disorder characterized by persistent eosinophilia without an identifiable underlying cause, leading to organ damage and dysfunction. The objectives of this study were to describe the real‐world demographics, patient journey, treatment patterns, and disease burden of patients ...
Juliana Schwaab, Paul Dolin, Bo Ding, Priya Jain, Lotte Westerink, Chris Edmonds, Tia Pennant, Oliver‐Thomas Carter, Fritha Hennessy, Stephanie Yanjing Chen   +9 more
wiley   +1 more source

Dissociated Biologic Responses Across the United Airway: A Case Report of Severe Asthma With Chronic Rhinosinusitis With Nasal Polyps and Eosinophilic Otitis Media

Respirology Case Reports, Volume 14, Issue 8, August 2026.
We report a case of severe asthma with chronic rhinosinusitis with nasal polyps and eosinophilic otitis media that was successfully controlled by switching biologic therapy from dupilumab to mepolizumab. Careful monitoring of disease activity and consideration of biologic switching may help achieve optimal control with currently available biologics ...
Tomoko Tajiri, Naoki Takemoto, Toshiya Minakata, Motohiko Suzuki, Yoshiyuki Ozawa, Hirotsugu Ohkubo   +5 more
wiley   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, Volume 67, Issue 5, Page 301-308, August 2026.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source